Hyperthermic isolated limb perfusion with tumor necrosis factor-alpha and melphalan in advanced soft-tissue sarcomas: histopathological considerations
- PMID: 10761796
- DOI: 10.1007/s10434-000-0155-1
Hyperthermic isolated limb perfusion with tumor necrosis factor-alpha and melphalan in advanced soft-tissue sarcomas: histopathological considerations
Abstract
Background: Hyperthermic isolated limb perfusion with tumor necrosis factor-alpha and melphalan was used as induction treatment in locally advanced extremity soft-tissue sarcomas for limb sparing surgery. The typical histopathological changes that occur in these tumoral masses are described in a series of 30 patients.
Methods: Fresh tumor specimens of 27 high grade extensive soft-tissue sarcomas and 3 recurrent desmoid tumors of the extremities were collected 6 to 8 weeks after hyperthermic isolated limb perfusion with tumor necrosis factor-alpha plus melphalan. The specimens were studied for surgical margins, extent and type of tumor necrosis, lymph node involvement, perineural and vascular invasion, and the effects on adjacent normal tissues such as nerves, muscles, and blood vessels.
Results: The typical histological changes were central cystic hemorrhagic necrosis with pericystic extensive fibrosis. Some nonspecific changes were noted in the soft tissues around the mass. In eight cases, more than 90% necrosis was found. In 17 cases, the extent of necrosis ranged between 60% and 90% (80%-90% in 4 of 17 cases). In five cases, less than 60% necrosis was noted. The best responses (>90% necrosis) were observed in distally located tumors. The responsive types were malignant fibrous histiocytoma, followed by myxoid liposarcoma and synovial sarcoma. Desmoid tumors showed less necrosis than high grade sarcomas. Vascular invasion was observed in two cases and intralesional venous thrombosis in one case. No perineural invasion or lymph nodes involvement were observed. The soft tissues adjacent to the tumor bed did not show major morphological changes. No correlation was found between the histological changes and each of the following: the anatomical (upper vs. lower limb) or compartmental location of the tumor; whether the tumor was primary or recurrent; and the types of previous treatment (systemic chemotherapy or radiotherapy) and tumor size.
Conclusions: This is the first serial histological description of the effects of tumor necrosis factor-alpha and melphalan administered via hyperthermic isolated limb perfusion on the tumoral masses of limb soft-tissue sarcomas. The small number of specimens and, especially, the variability of tumors preclude definite conclusions. Larger numbers and more homogeneity are needed in future studies.
Similar articles
-
High dose tumor necrosis factor-alpha and melphalan administered via isolated limb perfusion for advanced limb soft tissue sarcoma results in a >90% response rate and limb preservation.Cancer. 1997 Mar 15;79(6):1129-37. doi: 10.1002/(sici)1097-0142(19970315)79:6<1129::aid-cncr11>3.0.co;2-1. Cancer. 1997. PMID: 9070490
-
Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience.Ann Surg. 1996 Dec;224(6):756-64; discussion 764-5. doi: 10.1097/00000658-199612000-00011. Ann Surg. 1996. PMID: 8968230 Free PMC article. Clinical Trial.
-
Hyperthermic isolated limb perfusion with tumour necrosis factor and melphalan as treatment of locally advanced or recurrent soft tissue sarcomas of the extremities.Radiother Oncol. 1998 Jul;48(1):1-4. doi: 10.1016/s0167-8140(98)00040-1. Radiother Oncol. 1998. PMID: 9756165 Review.
-
Hyperthermic isolated limb perfusion with tumour necrosis factor-alpha and melphalan as palliative limb-saving treatment in patients with locally advanced soft-tissue sarcomas of the extremities with regional or distant metastases. Is it worthwhile?Arch Orthop Trauma Surg. 1998;118(1-2):70-4. doi: 10.1007/s004020050314. Arch Orthop Trauma Surg. 1998. PMID: 9833110
-
TNF-based isolated limb perfusion: a decade of experience with antivascular therapy in the management of locally advanced extremity soft tissue sarcomas.Cancer Treat Res. 2004;120:65-79. doi: 10.1007/1-4020-7856-0_4. Cancer Treat Res. 2004. PMID: 15217218 Review. No abstract available.
Cited by
-
Dynamic contrast-enhanced MR imaging in monitoring response to isolated limb perfusion in high-grade soft tissue sarcoma: initial results.Eur Radiol. 2003 Aug;13(8):1849-58. doi: 10.1007/s00330-002-1785-4. Epub 2003 Jan 8. Eur Radiol. 2003. PMID: 12942285
-
[Therapy-induced tumor regression in adult soft tissue sarcomas-morphological findings].Pathologe. 2004 Nov;25(6):437-44. doi: 10.1007/s00292-004-0720-7. Pathologe. 2004. PMID: 15449026 German.
-
The Wnt/β-catenin pathway in human fibrotic-like diseases and its eligibility as a therapeutic target.Mol Cell Ther. 2015 Jan 30;3:1. doi: 10.1186/s40591-015-0038-2. eCollection 2015. Mol Cell Ther. 2015. PMID: 26056602 Free PMC article.
-
The pathologic response of resected synovial sarcomas to hyperthermic isolated limb perfusion with melphalan and TNF-α: a comparison with the whole group of resected soft tissue sarcomas.World J Surg Oncol. 2013 Aug 12;11(1):185. doi: 10.1186/1477-7819-11-185. World J Surg Oncol. 2013. PMID: 23938063 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical